Botulinum toxin type A is widely used for treatment of facial rhytids, often in an “off-label” fashion. Important mechanisms of action and safety concerns for such treatments are presented along with recommendations for treatment of periorbital rhytids.
Get full access to this article
View all access options for this article.
References
1.
American Academy of Facial Plastic and Reconstructive Surgery 2002 Membership survey: trends in facial plastic surgery [news release]. Alexandria, Va: American Academy of Facial Plastic and Reconstructive Surgery; April 2003
2.
US Food and Drug Administration FDA Consumer Magazine. July-August 2002.
CarruthersJA, LoweNJ, MenterMA, et al. A multicenter, double-blinded, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002; 46:840-849. 12063480
5.
PalomaV, SamperA. A complication with aesthetic use of botulinum toxin type A: herniation of the orbital fat. Plast Reconstr Surg. 2001;107:1315 11379558
6.
MatarassoSL. Decreased tear expression with an abnormal Schirmer's test following botulinum toxin typeA for the treatment of lateral canthal rhytides. Dermatol Surg. 2002; 28:149-152. 11860426
7.
AhnMS, CattenM, MaasCS. Temporal brow lift using botulinum toxin A. Plast Reconstr Surg. 2000; 105:1129-1135. 10724275
8.
FrankelAS, KamerFM. Chemical browlift. Arch Otolaryngol Head Neck Surg. 1998; 124:321-323. 9525518
9.
ZesiewiczTA, StameyW, SullivanKL, HauserRA. Botulinum toxinA for the treatment of cervical dystonia. Expert Opin Pharmacother. 2004; 5:2017-2024. 15330738
10.
SpiegelJH, DerosaJ. The atomic relationship between the obicularis oculi muscle and the levator labii superioris and zygomaticus muscle complexes. Plast Reconstr Surg In press
11.
MatarassoSL, MatarassoA. Treatment guidelines for botulinum toxin typeA for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids. Plast Reconstr Surg. 2001; 108:208-214. 11420526
12.
FagienS. Discussion: treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptsosis following injections to the lateral canthal rhytids by SethL. MatarassoM.D., and Alan MatarassoM.D.Plast Reconstr Surg. 2001; 108:215-217
13.
Tang-LiuDD, AokiKR, DollyJO, et al.Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon. 2003; 42:461-469. 14529727
14.
NiamtuJIII. Botulinum toxin A: a review of 1,085 oral and maxillofacial patient treatments. J Oral Maxillofac Surg. 2003; 61:317-324. 12618971
15.
BorodicGE, FerranteR, PearceLB, et al. Pharmacology and histology of the therapeutic application of botulinum toxin. In: Janckovic J, Hallett M, eds. Therapy With Botulinum Toxin. New York, NY: Marcel-Dekker; 1994:119-157
16.
CarruthersJ, FagienS, MatarassoSL. Botulinum Toxin Type A Consensus Group Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg. 2004;114 (6 suppl) 1S-22S 15507786
17.
ShaariCM, GeorgeE, WuBL, BillerHF, SandersI. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope. 1991; 101:960-964. 1886444
18.
CarruthersJD, CarruthersA. Botulinum toxin in clinical ophthalmology. Can J Ophthalmol. 1996; 31:389-400. 8971462
19.
MacdonaldMR, SpiegelJH, RavenRB, KabakerSS, MaasCS. An anatomical approach to glabellar rhytids. Arch Otolaryngol Head Neck Surg. 1998; 124:1315-1320. 9865752
20.
GassnerHG, SherrisDA. Addition of an anesthetic agent to enhance the predictability of the effects of botulinum toxin type A injections: a randomized controlled study. Mayo Clin Proc. 2000; 75:701-704. 10907385
